ArticleOncotarget2017
Advanced alveolar soft part sarcoma responds to apatinib.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Assessment of Efficiency and Safety of Apatinib in Advanced Bone and Soft Tissue Sarcomas: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Camrelizumab Plus Apatinib in Advanced Unresectable Alveolar Soft Part Sarcoma and Undifferentiated Pleomorphic Sarcoma Patients: A Single-Center, Exploratory Case Series.Therapeutics and clinical risk management · 2026Trial
- Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy.Cancer biology & medicine · 2020Trial
- Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.The oncologist · 2019Trial
- Primary intracranial alveolar soft part sarcomas: a report of seven cases and a pooled analysis of individual patient data.Neurosurgical review · 2025Article
- Article
- The reversal of anti-HER2 resistance in advanced HER2-positive breast cancer using apatinib: two cases reports and literature review.Translational cancer research · 2022Article
- Efficacy and safety of apatinib in advanced refractory soft tissue sarcoma and association with histologic subtypes: a multicenter retrospective study.Annals of translational medicine · 2022Article
- Apatinib inhibits the growth of small cell lung cancer via a mechanism mediated by VEGF, PI3K/Akt and Ki-67/CD31.Journal of cellular and molecular medicine · 2021Article
- Combined immunotherapy and targeted treatment for primary alveolar soft part sarcoma of the lung: case report and literature review.Investigational new drugs · 2021Article
- Alveolar soft part sarcoma of the right calf: A case report.Medicine · 2020Article
- MiT/TFE Family of Transcription Factors, Lysosomes, and Cancer.Annual review of cancer biology · 2019Article
- Apatinib monotherapy for advanced VEGFR-2-negative nasopharyngeal carcinoma: A case report.Medicine · 2019Article
- Apatinib for salvage treatment of advanced malignant pleural mesothelioma: A case report.Medicine · 2018Article
- Efficacy and safety of apatinib in advance osteosarcoma with pulmonary metastases: A single-center observational study.Medicine · 2018Observational
- Apatinib as targeted therapy for sarcoma.Oncotarget · 2018Review
- Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study.Cancer biology & therapy · 2018Observational
- Alveolar soft part sarcoma occurring in the penis of a 3-year-old boy: A rare case report.Medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alveolar soft part sarcoma (ASPS) is a rare, hypervascular soft tissue sarcoma with a low chemotherapy response rate. Here, we report an ASPS case with multiple lung metastases on initial presentation. The primary tumor, a hypervascular soft tissue mass 4.1×3.2×2.0 cm, located in the right thigh, was resected prior to chemotherapy. The patient suffered disease progression after two cycles of gemcitabine-docetaxel treatment. Immunohistochemical examination of the tumor tissue revealed strong positive staining for vascular endothelial growth factor (VEGF) and VEGF receptor-2 (VEGFR-2). The patient was subsequently treated with apatinib (500 mg/day), a specific VEGFR-2 inhibitor. Treatment was well tolerated, and the patient exhibited a partial response, with the lung metastases reduced in size and number after one month of therapy. To date, 12-month progression-free survival has been achieved. Apatinib may provide an additional treatment option for metastatic ASPS, particularly in cases resistant to other chemotherapeutic options. Furtherstudies with more cases with longer follow-up times will be necessary to determine the clinical efficacy of apatinib for treatment of ASPS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.